Pulmatrix Inc. is a biotechnology company focused on the discovery and development of innovative inhaled therapies to address significant unmet needs in respiratory diseases. The company's primary function is to leverage its proprietary iSPERSE inhaled dry powder technology to create therapies that improve treatment delivery and efficacy. Pulmatrix aims to transform the treatment landscape for diseases such as chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fungal infections. By targeting the respiratory system directly, Pulmatrix's products hold the potential for faster and more efficient drug delivery, reducing systemic side effects. Headquartered in Massachusetts, Pulmatrix operates within the pharmaceutical and healthcare sectors, collaborating with research institutions and companies to advance its clinical programs. Its market significance is underscored by its commitment to enhancing patient care through innovative treatments specifically designed for pulmonary conditions.